- Trial phase
- Phase 3
- Time to market
- Phase 3 topline data expected in 2H 2028. If successful, an FDA submission and potential approval would follow, likely in 2029-2030 at the earliest.
- Why 4/10
- The next hard, dated binary catalyst (Phase 3 topline data from ACCOMPLISH-1/ACCOMPLISH-2) is expected in 2H 2028, more than 12 months away. Near-term events (ObesityWeek presentation on Nov 15, 2026 and supplementary Q4 readouts) are data presentations of existing or exploratory analyses, not pivotal binary readouts. Per the rubric, a mid-stage drug whose next catalyst is >12 months out scores 3-5; 4 reflects that aleniglipron is the company's lead asset but lacks a near-term binary catalyst.
Watch the ObesityWeek 2026 presentation on November 15 for any incremental efficacy or tolerability detail on aleniglipron, and the three supplementary data readouts due in Q4 2026 (body composition, sleep apnea, and other analyses). The next major binary catalyst is the Phase 3 ACCOMPLISH topline data in 2H 2028, leaving a long stretch where competitive developments from Lilly's Foundayo and Novo Nordisk's oral programs will likely drive sentiment more than company-specific news.
Price Chart
Executive Summary
Aleniglipron is Structure Therapeutics' lead asset: an oral small-molecule GLP-1 receptor agonist for obesity. Phase 2 data showed up to 16.2% weight loss at 72 weeks, among the highest reported for an oral GLP-1, with a tolerable side-effect profile. Phase 3 ACCOMPLISH trials are enrolling with topline data expected in 2H 2028. The company holds $1.24 billion in cash, funding operations through 2028. However, the stock has fallen from a $94.90 52-week high to ~$21 as Eli Lilly's competing oral GLP-1 (Foundayo/orforglipron) has already won FDA approval for obesity and is expanding into sleep apnea and diabetes. The GLP-1 market is intensely competitive, with Novo Nordisk and others also developing oral alternatives. Analyst consensus is Strong Buy with a mean target of ~$104, implying ~380% upside from the current price, but the next pivotal binary catalyst is roughly two years away.
How It Works
Aleniglipron is a once-daily oral pill that mimics a natural hormone called GLP-1, which tells the body to feel fuller longer, release more insulin, and slow digestion. Unlike injectable obesity drugs such as Wegovy and Ozempic, aleniglipron is a small molecule (not a peptide), so it can be taken as a simple pill with or without food rather than requiring an injection.
Trial Status
Aleniglipron completed a successful Phase 2 program (ACCESS and ACCESS II trials) showing up to 16.2% weight loss at 72 weeks in an open-label extension. The Phase 2b ACCESS trial (36 weeks) showed 12.1% weight loss at the highest dose, published in Nature Medicine in June 2026. The Phase 2 ACCESS II trial (44 weeks) showed placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg with no evidence of a weight-loss plateau. Two Phase 3 registrational trials, ACCOMPLISH-1 and ACCOMPLISH-2, are now enrolling patients, with topline data expected in the second half of 2028.
The Two-Sided Case
Upcoming Catalysts
- ObesityWeek 2026 presentation on November 15, 2026: Dose-Ranging Effects of Aleniglipron (the ACCESS Trials)
- Three supplementary aleniglipron data readouts due in Q4 2026 (body composition, sleep apnea, and other analyses per company guidance)
- Phase 3 ACCOMPLISH-1 and ACCOMPLISH-2 topline data expected in 2H 2028
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Structure Therapeutics Inc. PRESS-RELEASE GPCR ·Originating report